IL17A and psoriasis: The impact of the IL‐17A inhibitor secukinumab on adipose tissue and cutaneous inflammation in patients with moderate‐to‐severe psoriasis is being explored prospectively in the ongoing ObePso‐S trial (NCT03055494) (Korman, 2020).